An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more on the ta­ble

You can count the R&D ex­ecs at Ab­b­Vie among the be­liev­ers in Gen­mab’s bis­pe­cif­ic plat­form tech.

Mov­ing be­yond the Al­ler­gan buy­out, Ab­b­Vie re­fo­cused on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.